Author:
Facius Axel,Marostica Eleonora,Gardiner Philip,Watz Henrik,Lahu Gezim
Funder
Takeda Pharmaceuticals International GmbH, Zurich, Switzerland
AstraZeneca, Cambridge, UK
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference21 articles.
1. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2017.
www.goldcopd.org
. Accessed 12 May 2017.
2. Stockley RA. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin. 2009;25(5):1235–45.
3. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–96.
4. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38.
5. Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81–90.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献